Low-dose treatment of cervical XXXX , @entity9663 and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.

@entity1 @entity3519 @entity9663
Several studies support the hypothesis that low-dose botulinum toxin treatment may be as beneficial as high-dose regimen. Therefore, we studied 115 @entity1 (aged 27-84; mean 58.0, SD = 12.9 years; 68% females, 32% males) suffering from cervical @entity3519 (n = 66), @entity9663 (n = 28), and facial hemispasm (n = 21) over a period of 2 years in an open label, non-controlled pilot study. @entity1 received low-dose treatment with botulinum toxin type A (Dysport((R))). The toxin was diluted in 20 ml of 0.1% albumin solution to arrive at a concentration of 25 MU/ml and injected under EMG control. @entity1 responded to the treatment about 1 week after injection (mean 7.3 days, SD = 4.6). The mean duration of beneficial effects was 11.7 weeks (SD = 5.6). @entity1 evaluated the clinical global improvement on a scale ranging from 0 to 4. For the whole population, the mean was 2.7 points (SD = 1.1). In none of the subjects could antibodies to botulinum toxin type A be detected, and only a few side effects were observed. In conclusion, low-dose therapy with botulinum toxin A merits further controlled studies.
